Restoration of regulatory B cell deficiency following alemtuzumab therapy in patients with relapsing multiple sclerosis

BACKGROUND: Regulatory B cells (Bregs), which protect from autoimmunity, are deficient in multiple sclerosis (MS). Novel regulatory B cell subsets CD19(+)CD24(hi)CD38(hi) cells and CD19(+)PD-L1(hi) cells, with disparate regulatory mechanisms have been defined. Alemtuzumab provides a long-lasting sup...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Yeseul, Kim, Gayoung, Shin, Hyun-June, Hyun, Jae-Won, Kim, Su-Hyun, Lee, Eunjig, Kim, Ho Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206644/
https://www.ncbi.nlm.nih.gov/pubmed/30373595
http://dx.doi.org/10.1186/s12974-018-1334-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206644/
https://www.ncbi.nlm.nih.gov/pubmed/30373595
http://dx.doi.org/10.1186/s12974-018-1334-y

Ejemplares similares